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ABSTRACT
Objectives. The key to MR lymphography is suppression of T2* MR signal in normal
lymph nodes, while retaining high signal in metastatic nodes. Our objective is to
quantitatively compare the ability of ferumoxtran-10 and ferumoxytol to suppress the
MR signal in normal pelvic lymph nodes.
Methods. In 2010, a set of consecutive patients who underwent intravenous MR
Lymphography (MRL) were included. Signal suppression in normal lymph nodes in
T2*-weighted images due to uptake of USPIO (Ultra-Small Superparamagnetic Parti-
cles of Iron Oxide) was quantified. Signal suppression by two USPIO contrast agents,
ferumoxtran-10 and ferumoxytol was compared using Wilcoxon’s signed rank test.
Results. Forty-four patients were included, of which all 44 had a ferumoxtran-10 MRL
and 4 had additionally a ferumoxytol MRL. A total of 684 lymph nodes were identified
in the images, of which 174 had been diagnosed as metastatic. USPIO-induced signal
suppression in normal lymph nodes was significantly stronger in ferumoxtran-10 MRL
than in ferumoxytol MRL (p< 0.005).
Conclusions. T2* signal suppression in normal pelvic lymph nodes is significantly
stronger with ferumoxtran-10 than with ferumoxytol, which may affect diagnostic
accuracy.
Subjects Oncology, Radiology and Medical Imaging
Keywords MR lymphography, Lymph node metastases, USPIO contrast agents, Prostate cancer
INTRODUCTION
Prostate cancer (PCa) is the most common type of cancer and the second leading cause of
cancer death in men (Siegel, Miller & Jemal, 2015). The presence of lymph node metastases
is a poor prognostic factor, reducing treatment options. Conventional imaging modalities
such as CT orMRI rely on size and shape criteria to detectmetastatic lymph nodes, resulting
in poor sensitivity and specificity (Hövels et al., 2008; Heesakkers et al., 2008). Pelvic lymph
node dissection (PLND) is currently regarded as the gold standard for lymphnode staging in
PCa patients, but comes with increased costs and risk of morbidity (Heidenreich et al., 2011;
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Loeb, Partin & Schaeffer, 2010), and not all lymph node metastases are found at routine
PLND (Heesakkers et al., 2009). To select patients for PLND or elective nodal irradiation,
various nomograms (Partin et al., 1993; Partin et al., 1997) and numerical formulae (Roach
et al., 1994; Nguyen et al., 2009) are used to predict nodal involvement. However, these do
not provide information on the number, size, and location of metastatic nodes, which are
important parameters for staging (Cheng et al., 2012). 11C-choline PET/CT has been shown
to be more accurate than CT and MR (Schiavina et al., 2008), but has limited sensitivity in
the substantial group of smaller lymph node metastases <7 mm (Fortuin et al., 2012).
MR Lymphography (MRL) outperforms 11C-choline PET/CT by providing good accu-
racy for lymphnodeswell below 7mm.MRLuses a specific, Ultra-Small Superparamagnetic
Particles of Iron Oxide (USPIO) based contrast agent. USPIOs accumulate in macrophages
in normal lymphatic tissue, resulting in signal suppression on T2*-weighted MRI. Normal
lymph nodes become dark, and when fat-saturation is applied, fade into the background
of the surrounding dark fat. Thus, metastatic lymph nodes stand out with bright signal
intensity (SI) (Harisinghani et al., 1999). MRL properly performed and interpreted can
provide a high negative predictive value (NPV) (95–99%). A substantial amount of prostate
cancer patients can thus be spared a PLND procedure and the associated risk of morbidity.
Two MRL USPIO contrast agents can be currently used for humans. MRL using
ferumoxtran-10 (Combidex R©; SPL Medical, Nijmegen, The Netherlands) is the only
prospectively investigated imaging modality for assessing metastatic involvement of pelvic
lymph nodes, with sensitivities up to 91%, at 98% specificity (Harisinghani et al., 2003).
Despite these encouraging results, ferumoxtran-10 has not yet reached the market. Cur-
rently, ferumoxtran-10 is produced in The Netherlands by SPL Medical B.V. under GMP
(good manufacturing practice) conditions. The pharmacy of our institution takes care of
the supply of ferumoxtran-10 (for clinical routine and for clinical trials) for its patients in
accordance with the Dutch law.
The iron replacement drug ferumoxytol (Landry et al., 2005) (Feraheme R©, AMAG
Pharmaceuticals Inc, Cambridge, MA) has been proposed as a potential alternative MRL
contrast agent. In 2007, Harisinghani et al. (2007) concluded that ferumoxytol MRL
potentially identifies malignant lymph nodes. To the best of our knowledge however, no
prospective studies have yet been performed to validate the off-label use of this drug as an
MRL contrast agent. Moreover, the FDA has issued a warning considering its off-label use,
and explicitly recommends intravenous administration by a slow drip infusion: In the safety
announcement, issued on 30 March 2015, which is available on the website www.fda.gov,
it is stated that all IV iron products carry a risk of potentially life-threatening allergic
reactions, and that a Boxed Warning had been added to the prescribing instructions of
ferumoxytol that describes these serious risks and specifies a number of recommendations.
One of these recommendations is ‘Only administer diluted Feraheme as an IV infusion
over a minimum of 15 min. Feraheme should not be given as an undiluted IV injection.’
The purpose of this pilot study was to quantitatively compare ferumoxytol and
ferumoxtran-10 for use in MRL. The outcome measure was signal suppression in normal
lymph nodes, as this is the basis for discriminating metastatic and normal ones.
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Table 1 Scan parameters for Magnetic Resonance Lymphography.
Name Description Imaging
plane
Echo
time (ms)
Repetition
time (ms)
Flip angle
(deg)
Pixel size
(mm)
Matrix Slice
thickness
(mm)
Slices Bandwidth
(Hz/pixel)
VIBE T1-weighted
spin echo
Coronal 2.45 4.95 10 0.8× 0.8 320× 320 0.8 240 400
MEDIC T2*-weighted
gradient echo
Coronal 11 20 10 0.8× 0.8 320× 320 0.8 240 180
MATERIALS AND METHODS
This study retrospectively evaluated clinically obtained MRL data. The scientific use of
clinically obtained image data was approved by the Institutional Review Board. All patients
provided written informed consent for the use of the obtained data for research purposes.
Patient selection
Between January and April 2010, a set of consecutive patients who had been referred to the
Radboud universitymedical center, Nijmegen for clinically indicatedMRLwere included in
this retrospective study. The inclusion criteria were: (1) a histologically confirmed prostate
cancer with intermediate to high risk for nodal metastases; (2) a ferumoxytol MRL and/or
ferumoxtran-10MRL performed between January and April 2010; (3) successfully acquired
3D T1-weighted (‘‘VIBE’’) and 3D T2*-weighted (‘‘MEDIC’’) sequences available.
MRL protocol
The MRL protocol was as follows. USPIO contrast was administered intravenously, 36
to 24 h before the MRI was performed. Because of this time interval, only post-contrast
images were acquired. The same time interval was applied for both types of MRL. For
ferumoxtran-10 MRL, this has been established as the optimal interval. For ferumoxytol
MRL, this was considered optimal by our expert readers based on visual inspection of a set
of nine MRLs acquired from three patients at different time intervals post injection. One
patient was imaged at day 0 (directly post injection), at day 1, and at day 2, and the other
two were imaged at day 0, day 1, and day 3.
Immediately before imaging, Buscopan (20 mg i.v. and 20 mg i.m.) and Glucagon
(20 mg i.m.) were administered to suppress bowel peristalsis. The dose of ferumoxtran-10
was 2.6 mg Fe per kg body weight, conform earlier research (Harisinghani et al., 2003). The
dose of ferumoxytol was 6.0 mg Fe per kg body weight. This is the maximum allowed dose,
which was chosen to maximize the signal suppression in the MEDIC images.
Imaging was performed using a 3.0 T MR-scanner (Magnetom TrioTim; Siemens,
Erlangen, Germany). Scan parameters are listed in Table 1.
Interpretation of MRL images
The radiological diagnosis of the MRL examinations was established as the consensus
reading by two expert readers: an MD specially trained in reading MRL scans (OD, 2
years of MRL experience, >300 MRLs), and an abdominal radiologist (JB, >10 years of
MRL experience, >1,000 MRLs). The T1-weighted sequences (see Table 1) were used
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for localization and assessment of shape and size of the lymph nodes, and the iron-
sensitive T2*-weighted sequences were used to assess USPIO uptake, as described by
Heesakkers et al. (2008).
Quantitative MRL analysis
The contrast uptake in all detected lymph nodes was computed as follows. All lymph nodes
visible in the pelvic region were interactively segmented using the computer application
Lymph Node Task Card (Siemens,Malvern, PA). Segmentationwas performed based on the
T1-weighted images, in which all lymph nodes (normal as well as metastatic ones) appear
as hypointense structures. From these three-dimensional segmentations, the volume of
each lymph node was recorded automatically.
As a measure of contrast uptake, relative SI was computed rather than absolute SI.
Lymph node assessment based on relative SI (local fat calibrated lymph node assessment)
is more similar to visual assessment of the MRL image by a radiologist: visual assessment
is also based on a comparison of the SI of a lymph node with the SI of the surrounding
fat. Local fat calibration compensates for coil profiles and other factors creating a spatially
varying SI distortion in the images. The fat calibration was implemented by manually
segmenting a region of fatty tissue in the direct neighborhood of each lymph node. The
relative SI is calculated by subtraction of the mean SI of the local fatty tissue region from
the SI in the corresponding lymph node.
Statistical analysis
Relative SI in normal lymph nodes was compared using Wilcoxon’s signed rank test for
paired non-parametric data, using the statistical software package SPSS (version 20.0).
P-values >0.05 were considered statistically significant. Box-and-whisker plots were
constructed using the R Environment for Statistical Computing.
RESULTS
Forty-four patients fulfilled the inclusion criteria. All patients had prostate cancer staged
as Gleason Score 6 or higher. All underwent ferumoxtran-10 MRL, and four patients also
underwent ferumoxytol MRL. In all cases, ferumoxtran-10 MRL was performed first.
The time intervals between the two types of MRL for these four patients were as follows:
23, 130, 240, and 241 days (0.8, 4.3, 7.9 and 7.9 months) respectively. Median prostate
specific antigen (PSA) and Gleason Score were 9.5 (range 0.01–954.0) and 7 (range 6–9),
respectively. A total of 684 lymph nodes were identified in the MRL images, and 57 (8.3%)
of those belonged to patients who received both types of MRL. All 684 nodes were found
to be suitable for quantification of signal suppression. The readers diagnosed 174 lymph
nodes (25%) as positive (i.e., metastatic).
Median size (volume) of the positive lymph nodes was 0.14 ml (inter-quartile range
(IQR) 0.043–0.45) and median volume of the negative lymph nodes was 0.12 ml (IQR
0.045–0.30). A histogram of lymph node sizes is shown in Fig. 1.
Visual evaluation of the MEDIC images demonstrated that in ferumoxtran-10 MRL the
signal of normal lymph nodes was markedly suppressed; thus they were generally as dark
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Figure 1 Histogram of lymph node size. The volumetric length of a lymph node is defined as the cubic
root of its volume.
as the surrounding (suppressed) fatty tissue, whereas metastatic nodes remained visible
as bright structures. With ferumoxytol, normal nodes also had suppressed signal but the
suppression was less than with ferumoxtran-10, and they remained brighter than the fatty
tissue background, still apparent as hyperintense structures (Fig. 2).
The signal intensity box plot (Fig. 3) shows that with ferumoxtran-10, the interquartile
range (IQR) of normal lymph node intensity had an overlap with the IQR of fatty tissue
intensity. However, with ferumoxytol, the IQR of normal lymph nodes did not overlap
with the IQR of fatty tissue.
The difference in relative SI of normal lymph nodes between the two types of MRL was
significant. Relative SI was on average 39.7 (95% confidence interval (CI) [31.1, 48.3]) in
ferumoxytol MRL, and −2.1 (95% CI [−8.0–3.8]) in ferumoxtran-10 MRL (p< 0.005).
DISCUSSION
The results of this pilot study show, that relative SI in normal lymph nodes was significantly
higher in post-contrast ferumoxytol MRL than in ferumoxtran-10 MRL, both visually and
quantitatively (p< 0.005). TheMRL protocol used in this study included only post-contrast
imaging. However, as pre-contrast SI (whether absolute or relative) is not influenced,
of course, by the choice of contrast agent, pre-contrast SI would not differ between
ferumoxytol MRL and ferumoxtran-10 MRL, and any significant difference in relative SI
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Figure 2 Example of a normal lymph node in ferumoxtran-10MRL and ferumoxytol MRL. (A–C)
Overviews; (D–F) zoomed-in images. (A & D) USPIO-insensitive 3D T1-weighted (VIBE) sequence. The
lymph node is visible as a hypointense structure. (B & E) 3D T2*-weighted (MEDIC) sequence, enhanced
with ferumoxtran-10. The normal lymph node is as dark as the fat-suppressed fat and is thus indistin-
guishable from the background. (C & F) 3D T2*-weighted sequence, enhanced with ferumoxytol. Due to
contrast uptake, the normal lymph node is darker than it would have been in non contrast-enhanced MRI,
but it is not as dark as the background, and thus may be scored as metastatic.
refers to a difference in signal suppression. In other words, the difference in relative SI
found in our analysis implies that signal suppression was weaker for ferumoxytol MRL
than for ferumoxtran-10 MRL.
The underlyingmechanism causing the difference in signal suppression in normal lymph
nodes is not known. Possibly it can be explained by the different coating of the particles,
which may lead to different uptake by macrophages, or different clearance. A limited
number of studies have been published comparing ferumoxtran-10 and ferumoxytol asMR
contrast agent. Interestingly, both agents appear suitable for detection of macrophages in
atherosclerotic plaques (Herborn et al., 2006), and for detection of antigen-induced arthritis
(Simon et al., 2006). A possible explanation for the difference in behavior when used for
lymph node imaging may be the selective uptake of ferumoxtran-10, but not ferumoxytol,
by macrophages that migrate specifically to nodal tissue. This might be caused by the
different coatings of ferumoxtran-10, or by the different hydrodynamic diameter. In a
recent study comparing three USPIO’s in a porcine model, it was shown that differences
in hydrodynamic diameter were associated with significant differences in lymphatic iron
accumulation (Pouw et al., 2015).
The MR sequences used in this study have been validated in earlier research (Heesakkers
et al., 2008). One might argue that the lesser signal suppression in ferumoxytol MRL
could be improved by optimizing the sequences to make them more sensitive to USPIO.
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Figure 3 Tukey box plot comparing the signal intensities of lymph nodes and fatty tissue regions for
both contrast agents. F, fatty tissue regions; N, normal lymph nodes; M, metastatic lymph nodes; ftol, fer-
umoxytol; f10, ferumoxtran-10.
However, this would lead to an increase of artifacts related to bowel peristalsis, which
would deteriorate image quality.
The vast majority of the lymph nodes in our data set are of normal size (i.e., with
short-axis >10 diameter). As can be seen in Fig. 1, the distribution of lymph node size does
not differ substantially between positive and negative lymph nodes. This is in accordance
with the results reported by Tiguert et al. (1999), who analyzed 980 prostatectomy patients
and concluded that in normal-sized lymph nodes, size did not correlate with the presence
of metastasis.
This study has some limitations. In this pilot study, the number of patients was limited:
only four patients received both types ofMRL. However, by performing a quantitative anal-
ysis on a nodal level in the same set of node-by-node compared lymph nodes we were able
to perform a valid analysis of the differences. A total of 684 nodes, of which 57 were imaged
with both contrast agents, were analyzed, and demonstrated a significant difference in intra-
nodal signal suppression between the two contrast agents. In future studies, these results
need to be confirmed by including a larger number of patients with a ferumoxytol MRL.
Another limitation is that the optimal time interval—24 to 36 h—between contrast
administration and imaging has only been investigated qualitatively for ferumoxytol MRL.
As described in the Methods section, this interval was considered optimal based on visual
inspection of a set of ferumoxytol MRLs acquired after different time intervals, but a
quantitative investigation is needed to create a firmer basis for this choice.
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Radiologists who want to use ferumoxytol as an alternative to ferumoxtran-10 should
be aware that MRL with ferumoxytol as a contrast agent needs to be interpreted differently
even with identical MR sequences. In ferumoxtran-10 MRL, a lymph node that remains
bright is highly suspicious for metastasis, but this clear separation does not apply for
ferumoxytol MRL. Thus, the distinction between normal and metastatic nodes is less
straightforward. This is illustrated in Fig. 3, where the box plots of ferumoxytol-normal
and ferumoxytol-metastatic overlap substantially, which does not occur with ferumoxtran-
10. Thus, using ferumoxytol may lead to either many more false positives, or much
lower sensitivity. Considering the already relatively low PPV of 69% of ferumoxtran-10
(Heesakkers et al., 2008), a significant further decrease in PPV with ferumoxytol may be
problematic and lead to diagnostic inaccuracy or uncertainty. This is important because
ferumoxtran-10 is available on a limited scale, whereas ferumoxytol can be used off-label.
Thus, knowledge about the advantages and disadvantages of ferumoxytol is crucial.
In conclusion: USPIO-induced signal suppression in normal lymph nodes is significantly
weaker for ferumoxytol than for ferumoxtran-10, and therefore its discriminative
performance is likely to be lower. Therefore, the successful results reported in previous
studies regarding ferumoxtran-10 MRL cannot be extrapolated to ferumoxytol MRL.
Ferumoxytol MRL, when used in an off-label mode as a replacement for ferumoxtran-10
MRL, is likely to result in more false positives, and should not be used in clinical practice
for the diagnosis of metastatic lymph nodes without further scientific validation.
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